S
Shobanbabu Bommagani Institution-verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Researcher
faculty
7 h-index
36 pubs
269 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Shobanbabu Bommagani's research program focuses on drug discovery and development, particularly in the areas of cancer treatment and infectious diseases. His work involves investigating the molecular structure of therapeutic agents and their relationship to biological activity, often employing cell-based assays and structural biology techniques. Bommagani has published research on potential anti-cancer compounds, including sesquiterpenes, and has investigated the mechanisms of action for novel therapeutic strategies. His recent publications also include work on targeting viral proteins, such as the SARS-CoV-2 Nsp3 macrodomain, and evaluating the toxicity of drug delivery systems. Bommagani collaborates with researchers at the University of Arkansas for Medical Sciences, including Darin E. Jones, Abdul H. Khan, Abhishek Mishra, and John D. Imig. His scholarship metrics include an h-index of 7, with 36 total publications and 264 citations. He remains actively publishing, with his most recent work appearing in 2025.
Metrics
- h-index: 7
- Publications: 36
- Citations: 269
Selected Publications
-
EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage (2025)
-
Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors (2021)
-
Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone (2021)
Grants & Funding
Collaboration Network
Top Collaborators
Chris A. Brosey
2 shared publications
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
- Crystal structure of CoV-2 Nsp3 Macrodomain complex with PARG345
Andy Arvai
2 shared publications
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
- Crystal structure of CoV-2 Nsp3 Macrodomain complex with PARG345
Darin E. Jones
University of Arkansas for Medical Sciences
2 shared publications
In database
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
- EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage
John A. Tainer
2 shared publications
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
- Crystal structure of CoV-2 Nsp3 Macrodomain complex with PARG345
Zaineb A.F. Albayati
University of Arkansas for Medical Sciences
1 shared publication
In database
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Narsimha Reddy Penthala
University of Arkansas for Medical Sciences
1 shared publication
In database
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Ginell R. Post
University of Arkansas for Medical Sciences
1 shared publication
In database
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Mark S. Smeltzer
University of Arkansas for Medical Sciences
1 shared publication
In database
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Peter A. Crooks
University of Arkansas for Medical Sciences
1 shared publication
In database
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Jerry H. Houl
The University of Texas MD Anderson Cancer Center (US)
1 shared publication
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
Panagiotis Katsonis
Baylor College of Medicine (US)
1 shared publication
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
L.P.F. Balapiti-Modarage
University of Arkansas for Medical Sciences
1 shared publication
In database
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
Davide Moiani
The University of Texas MD Anderson Cancer Center (US)
1 shared publication
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
Albino Bacolla
The University of Texas MD Anderson Cancer Center (US)
1 shared publication
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
Todd Link
The University of Texas MD Anderson Cancer Center (US)
1 shared publication
- Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors
Similar Researchers
Based on overlapping research topics
Darin E. Jones
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Structure and Dynamics
SARS-CoV-2 and COVID-19 Research
Dylan S. Ogden
University of Arkansas at Fayetteville
Protein Structure and Dynamics
SARS-CoV-2 and COVID-19 Research
Microbial infections and disease research
Baha’a Jabali
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Protein Structure and Dynamics
Computational Drug Discovery Methods
Melissa M. Frangie
Arkansas State University
Cancer Treatment and Pharmacology
Drug-Induced Hepatotoxicity and Protection
Microbial infections and disease research
C.M. White
University of Arkansas – Fort Smith
Protein Structure and Dynamics
SARS-CoV-2 and COVID-19 Research
Computational Drug Discovery Methods
Sures Thallapuranam
University of Arkansas at Fayetteville
Protein Structure and Dynamics
SARS-CoV-2 and COVID-19 Research
Computational Drug Discovery Methods